Source Report

Data Moat Vulnerability to Roche Replication

Tempus AI's claimed data moat—built from 9M+ patient records with paired clinical-molecular data—is replicable by Roche, which owns Foundation Medicine (genomic sequencing) and Flatiron Health (oncology EMR data); Roche could integrate these via internal APIs like Flatiron's OncoEMR, which already embeds Tempus tests, eroding Tempus's exclusivity as pharma clients shift to cheaper in-house alternatives without licensing fees.[1][2][3]
- Roche acquired Flatiron (EMR data) and Foundation (genomics) for $4.3B combined in 2018, creating a vertically integrated dataset mirroring Tempus's multimodal approach.[4]
- Tempus integrates with Flatiron's OncoEMR for ordering/results, signaling interoperability that lets Roche aggregate Tempus data indirectly while building its own moat.[3]
- Competitors like Guardant (liquid biopsy) and Caris lack full clinical-genomic pairing, but Roche's scale (thousands of oncologists) enables rapid replication, with FMI seeing declining volumes as Tempus poaches share.[5]

Implications for Competitors/Entrants: Roche's combo already covers Tempus's core (sequencing + EMR), so new entrants must partner (risking data commoditization) or acquire scale via M&A; bears materialize if Roche launches a unified AI platform by 2027, capping Tempus data licensing at 30-38% YoY growth vs. management's 25%+ forever assumption.[6]

Customer Concentration in Pharma Licensing

Tempus derives ~25% of revenue ($316M in 2025) from Data & Applications, heavily concentrated in top pharma like AstraZeneca (11-12% of receivables, $200M deal), GSK ($70M), Pfizer; a single client pause (e.g., AZ/Pathos scrutiny in lawsuits) could slash 20-30% of this high-margin (74%) segment, as contracts include non-binding opt-ins and related-party risks flagged in SEC filings.[7][8]
- Top 10 customers ~24% of ARR; 19/20 largest pharmas license data, but AZ/Pathos deals (key to $1.1B TCV) face lawsuit claims of overstatement/round-tripping.[9][10]
- NRR 126% hides dependency: Insights grew 38-69% but excludes one-time warrants; Spruce Point notes weakening core ops masked by deals.[11]
- 70+ new 2025 deals, but biopharma R&D cuts (e.g., post-2025 slowdown) could trigger renegotiations.[12]

Implications for Competitors/Entrants: Concentration >20% exposes to client loss (e.g., if AZ builds internal via Pathos); materialize via 10-15% revenue miss if 2-3 pharmas cut spend amid trial failures, forcing diagnostics reliance (lower margins).

Lefkofsky's Founder Track Record

Eric Lefkofsky, Tempus CEO, cashed out $300M+ pre-IPO from Groupon (IPO $13B valuation, now <5%, down 95% post-IPO) and led InnerWorkings (restated financials, acquired at loss); Spruce Point flags pattern of "promoting disruptive tech, cashing out early, leaving shareholders losses," raising execution risk in Tempus's AI hype (only 2% revenue AI-derived).[13][4]
- 6 unicorns (InnerWorkings, Echo, Mediaocean, Groupon, Tempus, Pathos), but public ones cratered: Groupon SEC probes/accounting issues; InnerWorkings -92% post-report.[11]
- Tempus lawsuits echo: overstated AI/partnership revenue (AZ/Pathos), aggressive Ambry billing.[10]
- Post-IPO, stock volatile (19% drop on Spruce May 2025 report).[8]

Implications for Competitors/Entrants: Serial promoter risk means governance overhang; bears if Q1 2026 miss triggers restatements/lawsuits, eroding trust like Groupon.

High Cash Burn and Short Runway

2025 op cash burn $218M (FCF -$239M), net loss $245M despite $760M cash; acquisitions (Ambry, Paige) + AI infra spike investing CF to -$1.28B TTM, with debt covenants tied to revenue ($594M min 2025)—violation risks dilution if growth slows.[14][15]
- Q1 2025 burn >$100M; runway ~33 months at current rate, but legal ($10sM) + SBC ($200M 2026 guide) erode buffer.[10]
- Adj EBITDA -$7.4M 2025 (Q4 +$12.9M), guides $65M 2026 but misses "slightly positive" 2025 whisper.[16]
- No LT debt listed, but term loans ($460M+ post-Ambry) at high rates.[17]

Implications for Competitors/Entrants: Burn funds growth but covenants bind; materialize on reimbursement delay/guidance cut, forcing equity raise at discount.

Dilution from SBC and Offerings

SBC $534M (2024), Q4 2025 $48.7M alone (dilutes EPS); RSU settlements (13M+ shares post-IPO), convertible notes ($750M, cap price $111/share but dilutive on convert), secondary resale (1.27M shares); 2026 SBC guide $200M signals ongoing pressure.[18][19]
- Notes reduce dilution via capped calls, but conversion yields 15.7M shares max.[20]
- Prospectus: 22M ISO pool; post-IPO RSU net settlements dilute further.[21]

Implications for Competitors/Entrants: SBC >20% revenue dilutes insiders minimally but crushes EPS; bears if stock <conv price, triggering 10-15% share float increase.

Reimbursement and Payer Risks

No direct denials found, but aggressive Ambry billing flagged in lawsuits (unsustainable scrutiny); payer pushback looms on NGS/MRD (e.g., xT-CDx $4.5K Medicare vs. LDT $2.9K, but MRD constrained pre-reimbursement); SEC notes reliance on reimbursement growth.[8][22]
- ASP oncology +$60 to $1,590 Q1 2025 via xT-CDx migration (40% target), but hereditary ASP $770 moderates.[23]
- MRD volume capped until H2 2025 codes; general NGS headwinds (e.g., NeoGenomics).[24]

Implications for Competitors/Entrants: Diagnostics (75% rev) vulnerable; materialize on CMS cuts, dropping ASP 10-20%.

Overvalued at Optimistic Assumptions

7.5x P/S (vs. peers 5.3x) prices 30%+ growth/no profits thru 2028; analysts cut targets (Stifel $60, JPM $60) on "clouded visibility," Spruce 50-60% downside; DCF sensitive to margins (15% FCF unproven).[25][26]
- $1.3B 2025 rev (83% YoY) but GAAP losses; guides $1.59B/$65M EBITDA 2026 conservative?[16]
- Spruce: core genomics/data weak despite deals; stock -19% post-report.[13]

Implications for Competitors/Entrants: Premium assumes flawless execution; bears on 20% growth/negative EBITDA (e.g., litigation), compressing to 4x P/S ($30-40/share). Confidence: High on financials/lawsuits (SEC/earnings), medium on moat/reimbursement (inferential).

---

Recent Findings Supplement (March 2026)

Data Moat Defensibility Amid Roche Competition

Roche's Flatiron Health (real-world oncology EHR data from >5M patients) and Foundation Medicine (800K+ tumor genomic profiles) remain potent competitors, but no post-Sep 2025 evidence shows Roche replicating Tempus' multimodal (genomic + clinical + imaging) patient-linked dataset at scale; Tempus' acquisitions like Paige AI (Aug 2025, $81M for 7M pathology slides) and Ambry Genetics (early 2025) have instead widened its lead to 9M+ records, creating a flywheel where diagnostics feed proprietary data for pharma licensing—yet Roche's integrated ecosystem could erode this if it accelerates AI cross-pollination.[1][2][3]
- Tempus claims 60x larger paired clinico-genomic dataset vs. public benchmarks; Roche's assets are strong in silos (Flatiron EMRs, Foundation NGS) but lack Tempus' full integration.[4]
- Partnerships like AstraZeneca ($200M multimodal model, Apr 2025) validate moat, but Roche's internal use limits external threat visibility.[5]
For entrants, Roche's scale means data moats alone won't suffice—must pair with FDA-cleared AI (e.g., Tempus' xR IVD, Sep 2025) and pharma deals; replication risk materializes if Roche launches open-platform equivalents by 2027.

Reimbursement Delays Capping MRD and Sequencing Growth

Tempus continues gating MRD volumes (only small sales force active) pending MolDX reimbursement decisions, with Q4 2025 CRC assay in "back-and-forth" and tumor-naive NSCLC submission slated for 2026—despite 56% QoQ MRD growth to 4,700 tests, this self-imposed limit underscores payer hurdles persisting into 2026, as blended NGS reimbursement ($1,590 oncology, up from $1,500) lags peers and ADLT/FDA migrations drag.[6][7][3]
- Oncology NGS payment rate ~55% (2022-23 data); MRD lacks broad coverage, forcing disciplined rollout vs. full commercialization.[8]
- Q3 gross margins improved modestly but ASP lags signal no major payer wins yet; FY2025 diagnostics drove 111% growth but reimbursement is key margin lever.[9]
Competitors face same barriers, but delays materialize if MolDX denies CRC/NSCLC (H1 2026), capping diagnostics at <25% of $1.59B 2026 guide.

Pharma Licensing Revenue Concentration Risks

Data & Services (30.9% FY2025 growth to $316M) relies heavily on large pharma deals (e.g., AstraZeneca $220M min. spend, GSK $180M, Pathos related-party $41.7M in 9M), with Insights licensing up 38% but no disclosure of top-customer %—echoing partner Personalis' explicit "customer concentration" warnings, where enterprise deals (Natera, VA) comprise ~25% revenue; Tempus' $1.1B TCV includes 70+ pharmas but vulnerability rises if big contracts renegotiate amid 2028 patent cliffs.[10][8]
- Net retention 126% shows stickiness, but 49% TCV due next 12 months heightens renewal risk.[3]
- No single >10% flagged, but pharma-heavy mix (~Insights 69% Q4 growth ex-warrant) ties fortunes to R&D budgets.[3]
New players need diversified small/mid-pharma to compete; bear case if 2-3 majors cut (e.g., post-Keytruda), slashing 20-30% data revenue.

Elevated Cash Burn and Dilution Pressures Despite Cash Buffer

FY2025 operating cash burn hit $218M (up from prior), with net loss $245M driven by $136M stock comp/payroll taxes; Q4 adj. EBITDA turned +$12.9M but GAAP losses persist amid acquisitions (Paige, Ambry)—$760M cash provides ~2.8-year runway at current burn, but $343M ESOP shelf (Feb 2026) and $500M ATM remainder signal dilution ahead, compounded by insiders selling 596K shares (~$37.5M, last 3M) while owning 26%.[3][8][11]
- Debt/equity 252% ($1.2B debt vs. $491M equity); convertible notes ($728M net) add conversion overhang (~9.3M shares).[3]
- FY op cash flow -17% of revenue; 2026 $65M adj. EBITDA guide assumes discipline, but SBC unrecognized $297M over 2.5yrs pressures GAAP.[8]
Runway erodes if growth misses; dilution hits if ESOP/ATM taps amid volatility (beta 5.22).

Lefkofsky Track Record and Governance Scrutiny

Founder-CEO Eric Lefkofsky's Groupon baggage (post-IPO restatements, suits, control issues) lingers as "cleanest bear case," with Class B super-voting (30x) ensuring control; recent Spruce Point short (May 2025, alleging misleading AI revenue) sparked suits (dropped Nov 2025), but Feb 2026 GIPA class action over Ambry data transfer without consent revives privacy/governance risks tied to his Pathos ties ($41M related revenue).[2][12][13]
- Insider sales (e.g., Lefkofsky 166K shares Jan 2026) fuel optics amid $10B+ mkt cap.[14]
- No new Groupon-specific critiques post-Sep, but control + related-party deals invite SEC scrutiny.
Bear materializes on adverse GIPA ruling or Pathos unwind, eroding trust.

Valuation Pricing Optimistic 25%+ Growth Amid Execution Risks

At ~8x 2026E sales ($1.59B guide), TEM embeds 25% growth and $65M adj. EBITDA (~4% margin)—rich vs. peers (oncology diagnostics ~5x) given GAAP losses, burn, and no profitability inflection; post-Q4 stock -7.5% despite beat signals skepticism on dilution/ESOP, with analysts trimming targets (Stifel $60 from $85, Piper $80).[15][3]
- Consensus PT $87 (60% upside from ~$52), but DCF varies wildly (undervalued $138 vs. overvalued models); P/S 7.5x trails 2025 peak but premiums unproven moat.[16]
Bear unfolds if 2026 misses (e.g., reimbursement stalls), compressing to 4-5x on peers.